Logo-npj
Submitted: 18 Jun 2023
Accepted: 10 Aug 2023
ePublished: 22 Aug 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2024;13(1): e10630.
doi: 10.34172/npj.2023.10630
  Abstract View: 828
  PDF Download: 269

Review

Eculizumab in kidney diseases

Fatemeh Pour-Reza-Gholi 1 ORCID logo, Sara Assadiasl 2* ORCID logo

1 Department of Nephrology, Labbafinezhad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Sara Assadiasl, Email: saraasadiasl@gmail.com, , Email: assadiasl@sina.tums.ac.ir

Abstract

The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucidated. The high cost of eculizumab therapy and the rare adverse effects have created a paradox in conducting large clinical trials. Therefore, there is a need to increase clinicians’ awareness of the available data on the efficacy/safety of this drug in treating renal diseases. Herein, we have reviewed the outcomes of the administration of eculizumab in aHUS, PNH, lupus erythematosus nephritis, C3 glomerulonephritis, IgA nephropathy, and antibody-mediated rejection (AMR) in highly sensitized patients. Initial findings suggest its efficacy in treating acute injuries but lower effectiveness in preventing chronic lesions. Besides, early diagnosis and timely initiation of eculizumab are of particular importance.

Implication for health policy/practice/research/medical education:

Apart from the approved indications, eculizumab may help to treat complement-related kidney diseases. Eculizumab appears to be effective in treating acute injuries; however, it shows low efficacy in preventing chronic lesions. The high cost and low adverse effects of eculizumab are the main disadvantage and advantage of eculizumab therapy, respectively.

Please cite this paper as: Pour-Reza-Gholi F, Assadiasl S. Eculizumab in kidney diseases. J Nephropharmacol. 2024;13(1):e10630. DOI: 10.34172/npj.2023.10630.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 829

Your browser does not support the canvas element.


PDF Download: 269

Your browser does not support the canvas element.